ClinConnect ClinConnect Logo
Search / Trial NCT06888622

BLAZE-Limiting Approach in NMOSD

Launched by HUASHAN HOSPITAL · Mar 20, 2025

Trial Information

Current as of April 29, 2025

Completed

Keywords

Nmosd Eculizumab Aqp4 Ab Neuromyelitis Optica Spectrum Disorders

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • (1)Patients have been diagnosed with NMOSD and tested seropositive for AQP4 antibody; (2) Age ≥ 18 years; (3) Received eculizumab during an acute phase of NMOSD, defined as within 30 days of attack onset; (4) Adherence to an 8-week follow-up from eculizumab initiation.
  • Exclusion Criteria:
  • 1. Patients with unresolved Neisseria meningitidis infection or severe infections that preclude the use of immunotherapy;
  • 2. Patients with severe comorbidities (such as heart failure, respiratory failure, severe hepatic or renal dysfunction, etc.);
  • 3. Patients with incomplete records of clinical symptoms and signs, as well as insufficient data on serum marker tests in their medical records.

About Huashan Hospital

Huashan Hospital, affiliated with Fudan University in Shanghai, is a leading medical institution renowned for its commitment to innovative research and high-quality patient care. As a prominent clinical trial sponsor, Huashan Hospital leverages its extensive expertise in various medical disciplines to advance the development of new therapies and treatment modalities. The hospital's state-of-the-art facilities and multidisciplinary teams facilitate rigorous clinical investigations, ensuring adherence to ethical standards and regulatory compliance. With a focus on improving patient outcomes, Huashan Hospital actively collaborates with academic and industry partners to drive forward-thinking research initiatives that address critical healthcare challenges.

Locations

Shanghai, Shanghai, China

Patients applied

0 patients applied

Trial Officials

Chao Quan, Doctor

Principal Investigator

Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported